stockrowSerina Therapeutics, Inc.
Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.
- Revenue
- +2,500.0%
- EPS
- +16.7%
- Free cash flow
- −76.8%
Quarter to June 2026, against a year earlier
Follow SER
Alert me
Serina Therapeutics, Inc. (SER) Altman Z-score
Serina Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −22.07, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −22.07 | (8.63) |
| FY2024 | −13.44 | (8.73) |
| FY2023 | −4.71 | 54.79 |
| FY2022 | −59.50 | (3.39) |
| FY2021 | −56.11 | (15.83) |
| FY2020 | −40.28 | (27.28) |
| FY2019 | −13.01 | (26.20) |
| FY2018 | 13.19 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.36 | — | 0.43 | |
| Retained earnings / total assets | (9.14) | — | −12.79 | |
| EBIT / total assets | (3.46) | — | −11.40 | |
| Market value of equity / total liabilities | 2.79 | — | 1.67 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −22.07 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −50.64 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | 2.2× |
| GANX Gain Therapeutics, Inc. compare | −1.8× |
| HYPD Hyperion DeFi, Inc. compare | −8.4× |
| ATNM Actinium Pharmaceuticals, Inc. compare | −11.8× |
| SER Serina Therapeutics, Inc. | −22.1× |
| SGMOQ Sangamo Therapeutics, Inc. compare | −43.3× |
| BMEA Biomea Fusion, Inc. compare | — |
| LONA LeonaBio, Inc. compare | — |
| DWTX Dogwood Therapeutics, Inc compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets